Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 5
2009 4
2010 5
2011 4
2012 5
2013 8
2014 11
2015 14
2016 13
2017 12
2018 8
2019 19
2020 8
2021 12
2022 7
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 26916220

119 results

Results by year

Filters applied: . Clear all
Page 1
Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mizukami T, Togashi Y, Naruki S, Banno E, Terashima M, de Velasco MA, Sakai K, Yoneshige A, Hayashi H, Fujita Y, Tomida S, Nakajima TE, Fujino T, Boku N, Ito A, Nakagawa K, Nishio K. Mizukami T, et al. Mol Carcinog. 2017 Jan;56(1):106-117. doi: 10.1002/mc.22476. Epub 2016 Feb 24. Mol Carcinog. 2017. PMID: 26916220
Acquired resistance to EGFR-targeted therapies in colorectal cancer.
Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. Van Emburgh BO, et al. Mol Oncol. 2014 Sep 12;8(6):1084-94. doi: 10.1016/j.molonc.2014.05.003. Epub 2014 May 14. Mol Oncol. 2014. PMID: 24913799 Free PMC article. Review.
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
Napolitano S, Martini G, Rinaldi B, Martinelli E, Donniacuo M, Berrino L, Vitagliano D, Morgillo F, Barra G, De Palma R, Merolla F, Ciardiello F, Troiani T. Napolitano S, et al. Clin Cancer Res. 2015 Jul 1;21(13):2975-83. doi: 10.1158/1078-0432.CCR-15-0020. Epub 2015 Apr 2. Clin Cancer Res. 2015. PMID: 25838391
The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE. Bertotti A, et al. Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30. Nature. 2015. PMID: 26416732 Free PMC article.
Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases.
Owen DR, Wong HL, Bonakdar M, Jones M, Hughes CS, Morin GB, Jones SJM, Renouf DJ, Lim H, Laskin J, Marra M, Yip S, Schaeffer DF. Owen DR, et al. Cold Spring Harb Mol Case Stud. 2018 Apr 2;4(2):a002535. doi: 10.1101/mcs.a002535. Print 2018 Apr. Cold Spring Harb Mol Case Stud. 2018. PMID: 29438965 Free PMC article.
119 results